drugset / Trial / NCT01939171
Thymoglobulin in Cadaver Donor
Phase 2
Completed
20 enrolled
Instituto de Investigación Hospital Universitario La Paz
Hospital de Santa Maria, Portugal · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
To determine the efficacy and Security of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers in graft biopsies Security:To demonstrate that the administration of Thymoglobulin does not have side effects in renal recipients.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymoglobulin | Protein / enzyme biologic | 3 mg/kg | Intravenous |
Indications
No indication recorded.